al-Qassab H K, Findley L J
Department of Clinical Pharmacology, St Bartholomew's Hospital Medical College, London, UK.
Cephalalgia. 1993 Apr;13(2):128-31. doi: 10.1046/j.1468-2982.1993.1302128.x.
Thirty patients with severe classical and common migraine participated in a double-blind placebo-controlled cross-over study of migraine prophylaxis with propranolol LA (long-acting) 80 mg once daily, or propranolol LA 160 mg once daily or placebo. Each treatment was given for two months. There were no significant differences between the three treatment periods in headache frequency, headache severity, nausea frequency or severity. There was a non-significant trend for reduced duration of headache with the two doses of propranolol. The possible reasons for this negative effect are discussed. The safety of propranolol and its lack of serious side effects were demonstrated.
30名患有重度典型偏头痛和普通偏头痛的患者参与了一项双盲、安慰剂对照的交叉研究，该研究旨在探讨每日一次服用80毫克长效普萘洛尔、每日一次服用160毫克长效普萘洛尔或安慰剂预防偏头痛的效果。每种治疗持续两个月。在三个治疗阶段之间，头痛频率、头痛严重程度、恶心频率或严重程度均无显著差异。两种剂量的普萘洛尔在缩短头痛持续时间方面有不显著的趋势。文中讨论了出现这种阴性结果的可能原因。普萘洛尔的安全性及其缺乏严重副作用得到了证实。
